本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗，我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示，便表示您已接受我們的網站使用條款。 關閉
華盛頓2025年1月23日 /美通社/ -- 防禦技術公司Shield AI宣佈，其V-BAT無人航空系統（UAS）已被日本海上自衛隊（JMSDF）選定成為日本首個海上情報、監視與偵察（ISR）平台。V-BAT將為日本海上自衛隊（JMSDF）的水面艦艇提供先進的ISR能力，增強日本在印太地區的防禦姿態和作戰準備。 The V-BAT is the only single-engine, ducted-fan, vertical takeoff and landing (VTOL) UAS that is operationally deployed across multiple regions globally. 這一突破性協議標誌著計劃中多年的V-BAT訂單增長的開始，以支持日本海上自衛隊（JMSDF）的作戰需求。根據協議，日本海上自衛隊（JMSDF）將從Shield AI購買多架V-BAT UAS，提升其水面艦艇的監視和情報收集能力。 「日本是印太地區的重要盟友，對區域威懾行動至關重要，這一合作夥伴關係加強了日本應對危機的能力，並確保其配備了一個可靠且經過驗證的海上情報、監視與偵察（ISR）平台，」Shield AI總裁、聯合創始人及前海豹突擊隊成員Brandon Tseng表示。「日本海上自衛隊（JMSDF）選擇V-BAT，體現了他們對未來戰爭的理解——在這樣的戰爭中，作戰成功需要將高成本資產與智能且經濟的無人系統如V-BAT相結合。每一艘美國及盟國的海上艦艇都應該配備V-BAT，以在任何時候、任何地方提供艦載情報、監視與偵察（ISR）能力，而與日本海上自衛隊（JMSDF）一起實現這一願景令人振奮。」 V-BAT是唯一一款具單引擎、管道風扇設計、垂直起降（VTOL）能力的無人航空系統，並且在全球多個地區進行實際部署。憑藉其獨特的管道風扇設計和在狹小空間內的發射與回收能力，V-BAT特別適用於艦載和惡劣環境，確保在複雜任務中的靈活性和韌性。V-BAT以其可靠性而聞名，即使在GPS和通訊受限的環境中也能無懼運行。該系統在烏克蘭、黑海和印太地區等爭奪激烈的區域的驗證表現，證明了其能夠抵禦許多傳統無人機無法承受的先進電子戰威脅。 V-BAT提供的戰略能力相當於更昂貴的飛行器，並在情報、監視與偵察（ISR）、戰略打擊、搜索與救援以及海上攔截等多種任務中表現出色。其多功能性和尖端自主特性使其在現代防禦作戰中成為關鍵資產。 Shield AI簡介成立於2015年的Shield AI是一家獲風險投資支持的防禦技術公司，致力於通過智能系統保護軍人和平民。其旗艦自主軟件Hivemind驅動飛機、無人機及其他平台，能夠在爭奪激烈的環境中執行高可靠性的複雜任務。Shield AI在美國聖地亞哥、達拉斯、首都華盛頓特區及世界其他地區均設有辦事處，其產品積極支持全球美國及盟國的作戰。欲了解更多資訊，請瀏覽www.shield.ai。請在LinkedIn、Twitter和Instagram上關注Shield AI。 傳媒聯絡：Lily Hinz，media@shield.ai
WASHINGTON, Jan. 22, 2025 /PRNewswire/ -- Shield AI, the defense technology company building an AI-powered autonomy software platform and tools for the world, announced today that its V-BAT unmanned aircraft system (UAS) has been selected by the Japan Maritime Self-Defense Force (JMSDF) as the country's first-ever maritime-based intelligence, surveillance, and reconnaissance (ISR) platform. V-BAT will provide advanced ISR capabilities to JMSDF surface vessels, reinforcing Japan's defense posture and operational readiness in the Indo-Pacific region. The V-BAT is the only single-engine, ducted-fan, vertical takeoff and landing (VTOL) UAS that is operationally deployed across multiple regions globally. This milestone deal represents the beginning of a planned multi-year stream of increasing V-BAT orders to support JMSDF operations. Under the agreement, the JMSDF will acquire multiple V-BAT UAS from Shield AI, enhancing the surveillance and intelligence-gathering capabilities of its surface vessels. "Japan is a vital ally in the Indo-Pacific and critical to regional deterrence efforts, and this partnership strengthens Japan's ability to respond effectively to crises and ensures they are equipped with a reliable and proven platform for maritime ISR missions," said Brandon Tseng, Shield AI's President, Co-founder, and former Navy SEAL. "The JMSDF's selection of V-BAT reflects their understanding of the future of warfare—where operational success requires blending high-cost assets with intelligent, affordable unmanned systems like V-BAT. Every U.S. and allied maritime vessel should be equipped with V-BAT to provide shipborne ISR capabilities wherever and whenever they are needed, and it's fantastic to be making that vision a reality with JMSDF." The V-BAT is the only single-engine, ducted-fan, vertical takeoff and landing (VTOL) UAS that is operationally deployed across multiple regions globally. With its unique ducted-fan design and the ability to launch and recover in confined spaces, it is ideally suited for shipborne and austere environments, ensuring flexibility and resilience in complex missions. V-BAT has earned its reputation for reliability, operating with impunity even in GPS- and comms-denied environments. Its proven performance in contested regions like Ukraine, the Black Sea, and the Indo-Pacific demonstrates its ability to withstand advanced electronic warfare threats that have grounded many traditional drones. Delivering the strategic capabilities of much more expensive aircraft, V-BAT excels in missions ranging from ISR to strategic targeting, search-and-rescue, and maritime interdiction. Its versatility and cutting-edge autonomous features make it a critical asset in modern defense operations. About Shield AIFounded in 2015, Shield AI is a venture-backed defense technology company focused on protecting service members and civilians with intelligent systems. Its flagship autonomy software, Hivemind, powers aircraft, drones, and other platforms, enabling complex missions with high reliability in contested environments. With offices in San Diego, Dallas, Washington, D.C., and internationally, Shield AI's products actively support U.S. and allied operations worldwide. For more information, visit www.shield.ai. Follow Shield AI on LinkedIn, Twitter, and Instagram. Media contact: Lily Hinz, media@shield.ai
發炎肌膚專研ISR SKIN Health將於8月16日於台北信義區世貿一館2024台北國際美容美甲美髮 | 韓國美容展舉辦「敏感肌歡送趴踢」，邀請深受敏感肌所苦的朋友們一同吶喊心聲告別敏感肌，即日起填寫報名表單參與活動，當天身著藍色dress code進行闖關活動，更提供品牌專屬時尚小禮一份；若本身已是愛用者，只要現場提供分享見證，就可以將獨家保養品組合帶回家！(詳見官方活連結) ISR SKIN Health自2023年正式成立，在將滿周年之際特別參與2024台韓美容展，此次展覽集結國內百家知名品牌，同時引入歐美日韓人氣暢銷好物空運來台，包含：美容保養、美妝美甲、香氛SPA…等產品展出，對於關心保養的朋友們來說，可視為本年度絕不容缺席的保養盛會；ISR SKIN Health也很榮幸作為受邀品牌之一！ ISR SKIN Health從創立以來，矢志為敏感肌朋友解決保養難題，推出一系列專利胜肽修護精華，內含台灣生醫博土研發的專利阿芙因胜肽，可阻斷肌膚問題源頭，並由台灣知名美妝平台cosme試用者公開評測給予5顆星推薦，7天使用評估可確實穩定肌膚，達到亮顏保濕、淡化痘痘、減少粉刺等功效。 此次受邀參與美容展，也是ISR SKIN Health於2024年二度走向實體與大家近距離接觸。第一次在4月圓山花博的「女子月月有特展」創下單日單一展位最多人潮的佳績，並以「打擊敏感肌」為主軸廣邀各方朋友出拳擊潰問題肌。本次於台韓美容展所舉辦的「敏感肌歡送」派對，構想源自愛用者的支持與反饋，連續使用14天，達9成使用者確實達到肌膚穩定功效，舒緩敏弱達89%、賦活保濕97%及減緩痘痘85%，真正協助大家揮別敏感肌陰霾。 ISR SKIN Health認為保養之策「先修復再補給」先解決肌膚源頭問題，杜絕燥動因子的攻擊；同時修復已發生問題，前後攻防才能真正達到穩定肌膚之效。並以「輕簡保養法則」為敏感肌朋友提供最佳解方。「保養哲學也如中庸之道『過猶不及，適可而止』，肌膚調理也正如此道，所以每瓶精華液成份經不斷測試僅使用9-10種成份，盡可能降低致敏危肌。」此外，品牌更推崇簡化保養程序，僅在洗臉後使用精華液及乳液即可見效，不需過多的保養營養加重肌膚負擔！ 即日起，ISR SKIN Health誠摯邀請大家共襄盛舉，現場更不定時提供趴踢飲品，於8/14前成功預約活動的朋友，免費預約活動連結：https://www.isr-skin-health.com/event-list 更多ISR內容，請至官網查詢：https://www.isr-skin-health.com/
佛羅里達州坦帕2024年4月22日 /美通社/ -- 創新給藥技術先驅 Concept Medical 自豪地宣佈，已啟動其突破性 IDE 臨床研究「MAGICAL-ISR」，該項研究會使用 MagicTouch – 西羅莫司藥物塗層球囊 (DCB) 來治療冠狀動脈疾病的支架內再狹窄 (ISR)。用於 ISR 適應症的 MagicTouch 早前已獲得美國 FDA 的「突破性裝置」認可，隨後獲得研究裝置豁免 (IDE) 批准。首例患者由 Said Ashraf 博士（醫學博士 - 介入性心臟病學）及團隊在新澤西州大西洋城的 AtlantiCare 研究所完成註冊。 Concept Medical Announces First Patient Enrollment in Magical ISR IDE Study. MAGICAL-ISR 研究旨在評估西羅莫司 DCB 在治療 ISR 方面的安全性和有效性，專注於術後一年內避免目標病變失敗率 (TLF) 的患者比例。這項研究在受人尊敬的醫生 Martin Leon 博士、Azeem Latib 博士和 Ajay J. Kirtane 博士的指導下發起。 MagicTouch 代表在冠狀動脈介入治療領域取得革命性進步，提供了西羅莫司的受控和持續釋放，類似於藥物洗脫支架，但無需植入永久性支架。 「我們很高興地宣佈，採用了 MagicTouch 西羅莫司藥物洗脫球囊技術的 MAGICAL-ISR 研究招募到首名患者。這項重要的臨床試驗將預示著在各種臨床和解剖環境下開展安全有效的 DEB 治療時代，它將對美國複雜阻塞性冠狀動脈疾病患者的治療起到補充和改善作用。」紐約心血管研究基金會 (CRF) 研究主席兼創辦人 Martin Leon 博士表示。 Concept Medical 創辦人兼董事總經理 Manish Doshi 博士補充道：「MagicTouch 技術已在全球範圍內得到廣泛應用，透過這項研究進入美國市場，標誌著朝著解決 ISR 治療中未滿足的需求邁出了關鍵一步。我們對創新和患者安全的承諾堅定不移，我們預計這項研究將顯著影響全球 ISR 的治療方式。」 Concept Medical 憑藉全球首個西羅莫司藥物塗層球囊 MagicTouch 樹立行業標桿，該球囊已在國際上獲得廣泛採用，並榮獲 FDA 突破性認定。MAGICAL-ISR 研究以及其他正在進行的 IDE 臨床研究共同突顯該公司致力於臨床卓越和創新的承諾。 關於 Concept Medical： Concept Medical 的總部位於佛羅里達州坦帕，業務遍及全球。CM 致力於透過創新性研究和給藥技術的開發，為血管和非血管疾病提供更好的護理，並利用獨特的技術和產品組合以及專有的塗層技術，透過血管腔表面輸送藥劑，以此加強患者護理。Concept Medical 是世界上首個也是使用最廣泛的西羅莫司塗層球囊 MagicTouch 的創造者，其業務遍及歐洲、亞洲、拉丁美洲、中東以及全球所有其他獲得 CE 標誌的地區。 Concept Medical 的革命性技術結合了突破性產品 MagicTouch 和 Abluminus，已用於治療全球超過 50 萬名心血管疾病患者。 有關 MAGICAL-ISR 研究或 Concept Medical 創新解決方案的更多資訊，請瀏覽 www.conceptmedical.com。
TAMPA, Fla., April 20, 2024 /PRNewswire/ -- Concept Medical, a pioneer in innovative drug delivery technologies, proudly announces the commencement of its groundbreaking IDE clinical study, "MAGICAL-ISR" using MagicTouch – Sirolimus drug coated balloon (DCB), for the management of in-stent restenosis (ISR) in coronary artery disease. MagicTouch in ISR indication, had earlier been granted a 'Breakthrough Device' designation& later the Investigational Device Exemption (IDE)approval by the US FDA. The first patient enrollment was done at the AtlantiCare Institute, Atlantic City, NJ, by Dr Said Ashraf (MD - Interventional Cardiology) and team. Concept Medical Announces First Patient Enrollment in Magical ISR IDE Study. The MAGICAL-ISR study aims to assess the safety and efficacy of this Sirolimus DCB in treating ISR, focusing on the proportion of patients avoiding Target Lesion Failure (TLF) within one-year post-procedure. The study was initiated under the guidance of esteemed physicians Dr Martin Leon, Dr Azeem Latib and Dr Ajay J. Kirtane. MagicTouch represents a revolutionary advancement in coronary intervention, offering a controlled and sustained release of Sirolimus, akin to a drug-eluting stent but without the necessity of implanting permanent scaffold. "We are thrilled to announce the first enrollment of the MAGICAL-ISR study featuring the MagicTouch Sirolimus drug-eluting balloon technology. This momentous clinical trial will herald an era of safe and efficacious DEB therapy under a variety of clinical and anatomic circumstances to complement and improve the management of complex obstructive coronary disease for our patients in the United States." expressed Dr Martin Leon, Study Chair and Founder of Cardiovascular Research Foundation (CRF), New York. Dr Manish Doshi, Founder & Managing Director of Concept Medical added, "The MagicTouch technology has been embraced globally, and its entry into the US market through this study, represents a critical step towards addressing the unmet needs in ISR treatment. Our commitment to innovation and patient safety is unwavering, and we anticipate this study will significantly impact how ISR is treated worldwide." Concept Medical has set a benchmark with MagicTouch, the world's first sirolimus drug coated balloon, which has been widely adopted internationally and honoured with the FDA's Breakthrough Designation status. The MAGICAL-ISR study, alongside other ongoing IDE clinical studies, underscores the company's dedication to clinical excellence and innovation. About Concept Medical: Concept Medical is headquartered in Tampa, Florida, with a global presence. CM is dedicated to enhancing patient care through innovative research and development of drug delivery technology for vascular and non-vascular diseases, utilizing a unique combination of technology and products with proprietary coating technology that delivers pharmaceutical agents across the luminal surfaces of blood vessels. Concept Medical is the creator of MagicTouch, the world's first and most utilized Sirolimus Coated Balloon, with a presence in Europe, Asia, Latin America, the Middle East, and all other regions globally where the CE Mark is recognized. Concept Medical's revolutionary technology, featuring breakthrough products MagicTouch and Abluminus combined, has been utilized in treating over 500,000 patients worldwide for cardiovascular treatment. For more information on the MAGICAL-ISR study or Concept Medical's innovative solutions, please visit www.conceptmedical.com.
時序入秋，晝夜溫差拉大，擁有敏感肌膚的人，每逢換季就得面對皮膚鬧脾氣，出現乾癢、脫屑、泛紅等症狀，就像「水逆」一樣惹人心煩，其實肌膚問題一直都在，總搞得像水逆來亂！想要破解「肌關難題」，就讓發炎肌膚專研ISR SKIN Health專利胜肽修護精華水逆瓶來救援，打好肌底環境，從肌膚源頭阻斷躁動因子，賦活肌膚水、潤、膨、彈，重返年輕光采！ 舊肌喚新肌 阿芙因胜肽關閉躁動根源 台灣屬海島氣候，時節入秋冬氣候風向轉變，溼度降低；此外，秋季晝液溫差大，外在溫度的變化會影響皮脂分泌量，如果肌膚屏障力不足，油水難維持平衡，易對外在環境變化發生敏感症狀，像是乾燥脫屑、出油爆痘、泛紅…等。ISR SKIN Health建議敏感肌朋友面對換季應採取溫和保養，皮膚出油時不要過度清潔；皮膚乾燥也不要急著使用滋潤型保養品，可使用專利胜肽修護精華調理肌膚，內含專利阿芙因胜肽，可就肌膚解決根本問題。 台灣成大生醫博士團隊分析眾多肌膚問題，找出共同元兇-關鍵蛋白，會接受外來刺激因子，打開肌膚躁動開關，特採用實驗室仿生科技，氨基酸序列模倣人類特定蛋白，研發出易於肌膚吸收的阿芙因胜肽，注入在ISR SKIN Health專利胜肽修護精華中，可穩定與肌膚細胞互動，即便是換季引發的膚況問題，使用7-14天也能減少肌膚脫屑、乾燥、乾裂，平衡油脂分泌，增強肌膚對環境變化的耐受度與保護力。 精華液僅含9種成份 質純保養更安心 ISR SKIN Health專利胜肽修護精華專為問題肌的輕保養，採取「減法保養」原則，僅添加含阿芙因胜肽、歐盟有機認證玻尿酸及天然植萃成份，包含洋甘菊萃取、葡萄柚籽萃取…共9種成份，以降低肌膚保養風險，成份單純適用於醫美術後肌、敏弱肌及孕媽咪。 近年在醫美診所推廣也取得一致好評，年銷破萬，為使更多人接觸到阿芙因胜肽，ISR SKIN Health特選用新鮮子母瓶，保留胜肽活性，使用者在第一次使用時按壓瓶蓋搖勻再更換滴管，立即可以感受質純單一的胜肽修護活力，還能提昇後續保養成效，讓換季不再成為心中的刺。 現在就用ISR SKIN Health專利胜肽修護精華破解你的水逆 週年慶優惠中，買兩瓶更優惠，換季推坑趁現在：No.118 Choice選物網週年慶
ISR
請先登入後才能發佈新聞。
還不是會員嗎？立即 加入台灣產經新聞網會員 ，使用免費新聞發佈服務。 （服務項目） （投稿規範）
